Nursing Roles in Lipohypertrophy Prevention of Patients Receiving Insulin Injection

Main Article Content

Nayada Thanakijtummakul

Abstract

Lipohypertrophy (LH) is a common complication in patients with diabetes caused by insulin injections. As a result of the immune-mediated adverse effects of repeated insulin exposure. It occurs in subcutaneous tissue. The fat cells enlarge and proliferate resulting in an abnormal accumulation of fat underneath the surface of the skin. This effect makes insulin absorb slower and unpredictable, causing inappropriately high insulin requirements and unable to control blood sugar levels. Therefore, nurses need to have knowledge and understanding about the occurrence of lipohypertrophy and the correct insulin injection technique, including evaluating and examining insulin injection sites regularly. To be able to provide knowledge, improve awareness, and provide nursing care to prevent and reduce the incidence of lipohypertrophy in patients receiving insulin injection.

Downloads

Download data is not yet available.

Article Details

How to Cite
Thanakijtummakul, N. (2022). Nursing Roles in Lipohypertrophy Prevention of Patients Receiving Insulin Injection. JOURNAL OF PHRAPOKKLAO NURSING COLLEGE, 33(1), 251–263. Retrieved from https://he01.tci-thaijo.org/index.php/pnc/article/view/244383
Section
Academic Article (บทความวิชาการ)

References

วชิรญาณ์ การเกษ, และปัฐยาวัชร ปรากฎผล. (2560). ผลของการสอนฉีดยาด้วยนวัตกรรม GPs Insulin ต่อระดับน้ำตาลในเลือดผู้ป่วยเบาหวานที่ได้รับการรักษาด้วยยาฉีดอินสุลิน. วารสารการพยาบาลและการดูแลสุขภาพ, 35(3), 145–154.

สมาคมโรคเบาหวานแห่งประเทศไทย. (2559). คำแนะนำการฉีดยาเบาหวานสำหรับบุคลากรทางการแพทย์

(พิมพ์ครั้งที่ 2). กรุงเทพฯ: ผู้แต่ง.

Abu Ghazaleh, H., Hashem, R., Forbes, A., Dilwayo, T. R., Duaso, M., Sturt, J., … Mulnier, H. (2018).

A systematic review of ultrasound-detected lipohypertrophy in insulin-exposed people with diabetes. Diabetes Therapy, 9(5), 1741–1756. doi:10.1007/s13300-018-0472-7

AlJaber, A. N., Sales, I., Almigbal, T. H., Wajid, S., & Batais, M. A. (2020). The prevalence of lipohypertrophy and its associated factors among Saudi patients with type 2 diabetes mellitus. Journal of Taibah University Medical Sciences, 15(3), 224–231. doi:10.1016/j.jtumed.2020.03.006

American Diabetes Association. (2018). 6. Glycemic targets: Standards of medical care in diabetes–2018. Diabetes Care, 41(Suppl. 1), 55–64. doi:10.2337/dc18-S006

Basu, S., Yudkin, J. S., Kehlenbrink, S., Davies, J. I., Wild, S. H., Lipska, K. J., … Beran, D. (2019). Estimation of global insulin use for type 2 diabetes, 2018–30: A microsimulation analysis. The Lancet. Diabetes & Endocrinology, 7(1), 25–33. doi:10.1016/S2213-8587(18)30303-6

Blanco, M., Hernández, M. T., Strauss, K. W., & Amaya, M. (2013). Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism, 39(5),

–453. doi:10.1016/j.diabet.2013.05.006

Campinos, C., Le Floch, J. P., Petit, C., Penfornis, A., Winiszewski, P., Bordier, L., … Strauss, K. W. (2017). An effective intervention for diabetic lipohypertrophy: Results of a randomized, controlled, prospective multicenter study in France. Diabetes Technology & Therapeutics, 19(11), 623–632. doi:10.1089/dia.2017.0165

Dar, I. H., Dar, S. H., & Wani, S. (2013). Insulin lipohypertrophy: A non-fatal dermatological complication of diabetes mellitus reflecting poor glycemic control. Saudi Journal of Medicine & Medical Sciences, 1(2), 106–108. doi:10.4103/1658-631X.123646

Forum for Injection Technique. (2018). How to inject insulin. Retrieved from https://www.diabetescarecommunity.ca/living-well-with-diabetes-articles/medication-articles/fit/how-to-inject-insulin/

Frid, A. H., Hirsch, L. J., Menchior, A. R., Morel, D. R., & Strauss, K. W. (2016). Worldwide injection technique questionnaire study: Injecting complications and the role of the professional. Mayo Clinic Proceedings, 91(9), 1224–1230. doi:10.1016/j.mayocp.2016.06.012

Garg, S. K., Rewers, A. H., & Akturk, H. K. (2018). Ever-increasing insulin-requiring patients globally. Diabetes Technology & Therapeutics, 20(Suppl. 2), 21–24. doi:10.1089/dia.2018.0101

Gentile, S., Guarino, G., Della Corte, T., Marino, G., Fusco, A., Corigliano, G., ... & Strollo, F. (2021). Lipohypertrophy in elderly insulin-treated patients with type 2 diabetes. Diabetes Therapy, 12(1), 107–119. doi:10.1007/s13300-020-00954-3

Gentile, S., Guarino, G., Giancaterini, A., Guida, P., & Strollo, F. (2016). A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. SpringerPlus, 5(1), 563. doi:10.1186/s40064-016-1978-y

Gradel, A. K. J., Porsgaard, T., Lykkesfeldt, J., Seested, T., Gram-Nielsen, S., Kristensen, N. R., & Refsgaard, H. H. F. (2018). Factors affecting the absorption of subcutaneously administered insulin: Effect on variability. Journal of Diabetes Research, 2018, 1205121. doi:10.1155/2018/1205121

Gupta, S. S., Chaoji, S., Gupta, S., Gupta, K., & Gathe, S. (2019). 264-LB: Evaluation of awareness about insulin injection technique and prevalence of lipohypertrophy amongst insulin-taking diabetics in Central India. Retrieved from

https://diabetes.diabetesjournals.org/content/68/Supplement_1/264-LB.abstract

International Diabetes Federation. (2021). IDF Diabetes atlas 2021. Retrieved from

https://www.idf.org/e-library/welcome/

Ji, L., Sun, Z., Li, Q., Qin, G., Wei, Z., Liu, J., … Hirsch, L. J. (2017). Lipohypertrophy in China: Prevalence, risk factors, insulin consumption, and clinical impact. Diabetes Technology & Therapeutics, 19(1), 61–67. doi:10.1089/dia.2016.0334

Mokta, J. K., Mokta, K. K., & Panda, P. (2013). Insulin lipodystrophy and lipohypertrophy. Indian Journal of Endocrinology and Metabolism, 17(4), 773–774. doi:10.4103/2230-8210.113788

Nasser, J., Hammad, F., & Omran, A. (2017). Lipohypertrophy among insulin-treated patients. Bahrain Medical Bulletin, 39(3), 146–149. Retrieved from

https://www.bahrainmedicalbulletin.com/SEPT_2017/SEPT2017_LIPO.pdf

Olsen, N. (2018). Lipohypertrophy. Retrieved from https://www.healthline.com/health/diabetes/lipohypertrophy

Pozzuoli, G. M., Laudato, M., Barone, M., Crisci, F., & Pozzuoli, B. (2018). Errors in insulin treatment management and risk of lipohypertrophy. Acta Diabetologica, 55(1), 67–73.

doi:10.1007/s00592-017-1066-y

Sahasrabudhe, R. A., Limaye, T. Y., & Gokhale, V. S. (2017). Insulin injection site adverse effect in a type 1 diabetes patient: An unusual presentation. Journal of Clinical & Diagnostic Research, 11(8), 10–11. doi:10.7860/JCDR/2017/28919.10433

Sirma Medical Systems. (2019). Diabetes: M User’s Guide–Mobile. Retrieved from https://cdn.manula.com/user/14415/16633_18073_en_1541626079.pdf?v=20191209132345

Sürücü, H. A., & Arslan, H. O. (2018). Lipohypertrophy in individuals with type 2 diabetes: Prevalence and risk factors. Journal of Caring Sciences, 7(2), 67–74. doi:10.15171/jcs.2018.011

Thewjitcharoen, Y., Prasartkaew, H., Tongsumrit, P., Wongjom, S., Boonchoo, C., Butadej, S., ... Himathongkam, T. (2020). Prevalence, risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients with diabetes: An old problem in a new era of modern insulin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 4609–4620. doi:10.2147/DMSO.S282926

Tsadik, A. G., Atey, T. M., Nedi, T., Fantahun, B., & Feyissa, M. (2018). Effect of insulin-induced lipodystrophy on glycemic control among children and adolescents with diabetes in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Journal of Diabetes Research, 2018, 4910962. doi:10.1155/2018/4910962

Weatherspoon, D. (2019). What are the best insulin injection sites?. Retrieved from https://www.medicalnewstoday.com/articles/316618